Capricor Therapeutics (CAPR) News Today $12.52 -1.18 (-8.60%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Here's What HappenedCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Here's What HappenedMarch 5 at 2:06 PM | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Tuesday.March 5 at 12:40 PM | marketbeat.comCapricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD TherapyMarch 5 at 4:33 AM | msn.comCapricor Therapeutics stock rises on FDA priority reviewMarch 4 at 6:32 PM | investing.comCapricor Therapeutics' Cell Therapy for Muscular Dystrophy Patients to Get FDA Priority ReviewMarch 4 at 6:32 PM | marketwatch.comCapricor Therapeutics Shares Rise on FDA Priority ReviewMarch 4 at 6:32 PM | marketwatch.comCapricor announces FDA acceptance, Priority Review for deramiocel BLAMarch 4 at 6:32 PM | markets.businessinsider.comCapricor: Further Value Unlocked With Priority Review Of DeramiocelMarch 4 at 6:32 PM | seekingalpha.comInvestors Buy High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR)March 4 at 4:17 AM | americanbankingnews.comOppenheimer & Co. Inc. Buys 35,823 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)Oppenheimer & Co. Inc. increased its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 52.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,231 shares of the biotechnology company's stoMarch 4 at 3:50 AM | marketbeat.comCapricor Therapeutics (CAPR) to Release Earnings on ThursdayMarch 4 at 3:41 AM | americanbankingnews.comCapricor Therapeutics Target of Unusually High Options Trading (NASDAQ:CAPR)Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) saw unusually large options trading on Monday. Stock traders acquired 4,400 call options on the company. This is an increase of 37% compared to the average daily volume of 3,206 call options.March 3 at 11:35 AM | marketbeat.comCapricor Therapeutics options imply 31.0% move in share price post-earningsFebruary 27, 2025 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Shares Down 4.8% - Here's WhyCapricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.8% - Time to Sell?February 27, 2025 | marketbeat.comCapricor Therapeutics (CAPR) Expected to Announce Earnings on ThursdayCapricor Therapeutics (NASDAQ:CAPR) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comIs Capricor Therapeutics, Inc. (CAPR) the Best Small-Cap Growth Stock to Buy Now?February 26, 2025 | insidermonkey.comCapricor Therapeutics (NASDAQ:CAPR) Trading Up 8.4% - Should You Buy?Capricor Therapeutics (NASDAQ:CAPR) Trading 8.4% Higher - Should You Buy?February 25, 2025 | marketbeat.comBlack Diamond Financial LLC Takes $3.83 Million Position in Capricor Therapeutics Inc (NASDAQ:CAPR)Black Diamond Financial LLC acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 277,737 shares of the biotechnology company's stock, valued at aFebruary 24, 2025 | marketbeat.comCapricor Therapeutics: Heavily Derisked After BLA Submission And OLE DataFebruary 23, 2025 | seekingalpha.comCapricor Therapeutics (NASDAQ:CAPR) Shares Down 6.9% - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.9% - Time to Sell?February 19, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Given Average Rating of "Buy" by BrokeragesCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has earned a consensus rating of "Buy" from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price target among analysts that hFebruary 14, 2025 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.2% - Still a Buy?Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.2% - Still a Buy?February 12, 2025 | marketbeat.comCapricor Therapeutics to Participate in Upcoming Investor ConferencesFebruary 10, 2025 | finance.yahoo.comCapricor Therapeutics (NASDAQ:CAPR) Shares Down 6.1% - Here's WhyCapricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.1% - Here's What HappenedFebruary 5, 2025 | marketbeat.comVanguard Group Inc. Increases Stake in Capricor Therapeutics Inc.January 31, 2025 | gurufocus.comJPMorgan Chase & Co. Purchases 45,381 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)JPMorgan Chase & Co. raised its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 419.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 56,199 shares of the biotechnology company's stock after purchasing an additional 45,381 sharJanuary 26, 2025 | marketbeat.comMagnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)Magnus Financial Group LLC acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the biotechnology company'sJanuary 23, 2025 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week aloneJanuary 22, 2025 | uk.finance.yahoo.comBrokers Issue Forecasts for CAPR FY2025 EarningsCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biotechnology compaJanuary 22, 2025 | marketbeat.comKrilogy Financial LLC Makes New Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)Krilogy Financial LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,800 shares of the biotechnology company's stock, valued atJanuary 20, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of "Buy" by BrokeragesCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objective among anJanuary 20, 2025 | marketbeat.comBarclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)Barclays PLC lifted its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 106.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,296 shares of the biotechnology company's stock after buying anJanuary 18, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short InterestCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 7,950,000 shares, an increase of 42.2% from the December 15th total of 5,590,000 shares. Based on an average trading volume of 1,670,000 shares, the short-interest ratio is presently 4.8 days.January 15, 2025 | marketbeat.comExosome Therapies Market Poised for Explosive Growth During the Study Period (2025-2034) | DelveInsightJanuary 13, 2025 | ca.finance.yahoo.comCapricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading Volume - Time to Buy?Capricor Therapeutics (NASDAQ:CAPR) Sees Large Volume Increase - What's Next?January 3, 2025 | marketbeat.comCapricor Completes Submission Of BLA For Deramiocel For Treatment Of Duchenne Muscular DystrophyJanuary 3, 2025 | markets.businessinsider.comCapricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s ExcitedJanuary 3, 2025 | msn.comCapricor completes U.S. marketing submission for lead candidateJanuary 2, 2025 | msn.comCapricor Therapeutics: Strategic Advances and Regulatory Progress Drive Buy RatingJanuary 2, 2025 | markets.businessinsider.comCapricor Therapeutics completes submission of BLA to FDA for deramiocelJanuary 2, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR)HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday.January 2, 2025 | marketbeat.comCapricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyJanuary 2, 2025 | globenewswire.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 26.8% in DecemberCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 5,590,000 shares, a growth of 26.8% from the November 30th total of 4,410,000 shares. Based on an average daily volume of 3,570,000 shares, the short-interest ratio is currently 1.6 days.December 29, 2024 | marketbeat.comState Street Corp Has $7.79 Million Position in Capricor Therapeutics Inc (NASDAQ:CAPR)State Street Corp increased its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 27.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 512,313 shares of the bioteDecember 28, 2024 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of "Buy" from BrokeragesCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price targeDecember 26, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9% - What's Next?Capricor Therapeutics (NASDAQ:CAPR) Shares Down 2.9% - Here's What HappenedDecember 24, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Trading Up 5.6% - Time to Buy?Capricor Therapeutics (NASDAQ:CAPR) Trading 5.6% Higher - What's Next?December 23, 2024 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 14.5% in NovemberCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 4,410,000 shares, an increase of 14.5% from the November 15th total of 3,850,000 shares. Based on an average trading volume of 3,430,000 shares, the short-interest ratio is presently 1.3 days.December 16, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Down 5.3% - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Shares Down 5.3% - Time to Sell?December 13, 2024 | marketbeat.com250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P.Point72 Asset Management L.P. bought a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 250,204 shares of the biotechnology company's stock, valued at approDecember 9, 2024 | marketbeat.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.650.69▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼184▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EWTX News Today PTGX News Today MIRM News Today ARWR News Today LGND News Today CNTA News Today AGIO News Today NAMS News Today HRMY News Today BLTE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 3/5/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPR Stock Alerts